Zeta CTLA-4 Antibody. Zeta’s rabbit recombinant IVD antibody binds Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), a member of the CD28 superfamily and is an inhibitory regulator of T cell-mediated immune responses. CTLA-4 is expressed almost exclusively on CD4+ and CD8+ T-cells and is crucial in the maintenance of T-cell homeostasis. Additionally, CTLA-4 IHC can be used to reliably label lymphocytes in FFPE human tissues, making it possible to investigate the role of CTLA-4 in the tumor microenvironment.
CTLA-4 expression is induced on the surface of T cells after CD28 binding and activation. It is constitutively expressed in T-regulatory cells, acting as an immune checkpoint inhibitor and downregulating T-cell activity. CTLA-4 primarily inactivates T-cell activity by competing with the CD28 costimulatory molecule. CD28 and CTLA-4 share the identical ligands of CD80 and CD86 on antigen-presenting cells; thus, CTLA-4 competes with CD28 function in T-cell survival, proliferation, and recruitment. In particular, CTLA-4 down-modulates CD4+ helper T-cell activity and enhances Treg immunosuppressive functions. CTLA-4 has been shown to play a role in human diseases. CTLA-4 acts as a physiological brake on the activated immune system to maintain immune homeostasis. Several suppressive mechanisms for T-cell functions have been attributed to CTLA-4.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.